Caution needed when assessing impact of dosing errors in clinical trials

November 13, 2000

NEW ORLEANS - When addressing the issues of cause and effect in clinical research, particularly when dosing errors are involved, care must be taken to ensure that potential confounding issues also are considered, according to Duke University Medical Center researchers.

At issue is a group of drugs known as "clot-busters," which are used by physicians to dissolve life-threatening blockages in arteries around the heart. Many patients brought to emergency rooms with symptoms of heart attacks are given these drugs in an attempt to open blocked arteries and keep the heart from being starved of oxygen-rich blood.

Earlier this year, a well-publicized study found that dosing errors are common and that these errors are associated with twice the mortality. The conclusion was that errors in doses caused the higher mortality. These results were used to support a shift to the more simple bolus (single injection) drugs and to drugs that do not require weight-adjusted dosing.

In their new analysis, the Duke researchers determined that the worst outcome among patients who had dosing errors appears not to be caused by the dosing errors themselves. The sicker patients tended to be treated more often with the wrong dose, but their higher mortality can largely be explained by the fact that they were sicker to begin with, according to Dr. Christopher Granger, cardiologist at Duke's Clinical Research Institute (DCRI), who prepared the results of his study for presentation Tuesday at the 73rd annual scientific sessions of the American Heart Association.

Therefore, although minimizing dosing errors remains an important goal, this example underscores the importance of careful analysis before proclaiming a health concern and a possible solution, he said.

"The general issue of medical errors is important and is one that is receiving a lot of attention," Granger said. "When we are associating adverse outcomes with a particular therapy, we need to be careful in ascribing cause without first assuring ourselves that there aren't major unmeasured confounding issues involved."

In his analysis, Granger looked at the database of ASSENT-2, a multi-center international trial conducted from 1997 to 1998 that involved 16,949 patients brought to emergency rooms within six hours of acute heart attack symptoms. Patients were randomized to one of two clot-busters: t-PA, or TNK, a newer and genetically modified version of t-PA.

The original ASSENT-2 trial was funded by Genentech, South San Francisco, Calif., and Boehringer Ingelheim, Ingelheim, Germany. Granger's analysis of the data was supported by the DCRI.

ASSENT-2 was designed as a double-blind, double-dummy trial, in which patients either received t-PA and placebo TNK, or TNK and placebo t-PA. This was done because the two drugs are administered differently, and trial designers wanted to ensure that researchers wouldn't know which active drug each patient received.

While ASSENT-2 demonstrated that TNK was just as effective in the acute treatment of heart attack as t-PA, Granger wanted to find out the effects of dosing of the two drugs, which are markedly different. For t-PA, physicians gave one injection of the drug, followed by a 90-minute intravenous drip, the dose of each being determined by a formula in which weight is an important variable. Patients receiving TNK received one of five pre-determined five-second doses, based on where they fall in a range of weights.

Overall, 95.1 percent of the ASSENT-2 patients received the correct dose of t-PA, while 96.4 percent received the correct dose of TNK.

"If incorrect dosing was responsible for the adverse outcomes, the relationship would be stronger for patients who received the wrong dose of the active agent when compared to those receiving the wrong dose of the placebo," Granger said. "If there were major confounding issues, one might expect similar outcomes for misdosing active drug and placebo."

As it turned out, the researchers found that 30-day mortality was in fact higher when patients received either too little (19.5 percent mortality) or too much (9.8 percent mortality) t-PA, compared to the correct amount (5.4 percent mortality). Surprisingly, however, the same relationship existed for placebo - patients who were given too little or too much had higher mortality than the correct amount (23.5 percent or 10.0 percent compared to 5.4 percent).

"We saw the same relationship of misdosing and bad outcomes with the active drug and the placebo, suggesting that most of the association was due to confounding issues rather than the result of wrong doses," Granger said.

Granger said he believes that part of the explanation is that patients who got the wrong dose had higher-risk features such as older age, lighter body weight and were more likely female. The other part is due to the fact that during the 90-minute infusion of t-PA, if the patient became unstable with bleeding or other instability, the drug may have been stopped, but the bad outcome was due to the problem that led to the drug being stopped, not to the discontinuation itself.

In general, fewer patients treated with TNK received the wrong dose, which was likely related to its simple single 5-10 second dosing, researchers said.
-end-


Duke University Medical Center

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.